

RENAL ANGINA IN CRITICALLY ILL PATIENTS: EXPLORATORY ANALYSIS OF TWO PREDICTION TOOLS IN FUNDACION CARDIOINFANTIL IN BOGOTA - COLOMBIA.



José García-Habeych¹, Juan Castellanos De la Hoz¹, Noelia Niño³, Luis Castro⁴, Juan Pablo Montoya⁴, Sandra Saumett⁴, Santiago Varón⁵, Laura Gutierrez Castro⁶, Carlos Martinez⁶, Manuel Antonio⁶, Eduardo Zúñiga^{1,3}, Alejandra Molano-Triviño * ^{1,2,3}, Gregorio Romero; Claudio Ronco²

1. Internal medicine and Nephrology Fundación Cardioinfantil IC Bogotá – Colombia, 2. International Renal Research Institute Vicenza, San Bortolo Hospital, Vicenza, Italy, 3. Renal Care Services, Colombia, 4. Medicine. Universidad del Rosario, Bogotá, Colombia. 5. Medicine, Universidad de la Sabana, Bogotá, Colombia. 6. Internal Medicine, Universidad del Rosario, Bogotá, Colombia.

Background: AKI implies clinical and economical repercussions. The use of biomarkers economically limited, so is mandatory to use resources wisely, according to worse clinical scenarios through prediction tools that allow selecting patients with higher benefit from interventions to reduce morbidity derived from AKI.

Methods: From our database, we searched adult ICU patients (February to June 2020), excluding those at ICU admission with diagnosis of AKI, serum creatinine >2,5mg/dl, dialysis or kidney transplantation. We evaluate the performance of the Renal Angina Index (RAI), and Acute Kidney Injury Predictor (AKI predictor), to predict severe AKI (KDIGO 2 and 3) at 7 days of follow-up in ICU patients.

Results: A total of 74 patients (72.5%) had severe AKI at 7 days. The ROC AUC for the RAI and AKI predictor score was 0.487 (95% CI 0.363 - 0.61) and 0.62 (95% CI 0.502 - 0.737) respectively. A probability of AKI by the AKI predictor tool of 27% or less had a sensitivity of 43.3% and a negative LR of 0.69.



Conclusion: In this exploratory analysis, RAI doesn't discriminate between patients progression risk to severe AKI. An AKI predictor risk lower than 27% suggests that patients won't progress to severe AKI and doesn't require further biomarkers.

*alepatrimoltri@gmail.com

38th Vicenza Course on AKI&CRRT
a week of virtual meetings

2-6 November 2020